Rikuto Masuda

Mr. Rikuto Masuda

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 October 2025 in Journal of Affective Disorders
Verified
Journal Article
Closed access
Yoshihiro noguchiYoshihiro noguchi
Yoshihiro noguchi
AOAi Oonishi
Ai Oonishi
RMRikuto Masuda
Rikuto Masuda
KMKoki Mori
Koki Mori
MKMichio Kimura
Michio Kimura
TYTomoaki Yoshimura
Tomoaki Yoshimura

25 September 2025 in Oncology
Verified
Journal Article
Closed access
TSTomoya Sugimoto
Tomoya Sugimoto
Yoshihiro noguchiYoshihiro noguchi
Yoshihiro noguchi
RMRikuto Masuda
Rikuto Masuda
THTomohiko Harada
Tomohiko Harada
YTYukio Toyama
Yukio Toyama
TYTomoaki Yoshimura
Tomoaki Yoshimura
Introduction: This study aimed to evaluate the trends in safety signal detection of osimertinib compared with other epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) through volcano plot analysis, using data from the Japanese Adverse Drug Event Report (JADER) and FDA Adverse Event Reporting System (FAERS). The overall objective of this study was to identify the potential risks associated with osimertinib-induced adverse events. Methods: Data were retrieved from the JADER (Q1 2004–Q1 2024) and FAERS (Q4 1997–Q2 2024) databases. The target drugs were osimertinib, gefitinib, erlotinib, and afatinib. Adverse event reports were standardized by converting all records in the database to the preferred terms of the International Classification of Diseases and subsequently mapping them to the high-level terms (HLTs) of the Medical Dictionary for Regulatory Activities. Volcano plots of odds ratios and z scores were generated to assess variations in detection trends between osimertinib and the abovementioned three EGFR-TKIs. The top 20 HLTs that demonstrated significant safety signals were computed and compared. Results: The numbers of safety signals detected in the JADER for osimertinib compared to the aforementioned EGFR-TKIs following volcano plot analysis were 24, 20, and 16, whereas detected safety signals were 7, 43, and 14 in FAERS. In the JADER database, the most frequently reported adverse reactions for osimertinib included “poisoning and toxicity” and “heart failure.” Conversely, in the FAERS database, the predominant adverse reactions were “death and sudden death” and “marrow depression and hypoplastic anemias.” Conclusion: This study confirmed an increased frequency of reports linking osimertinib to cardiotoxicity, bone marrow suppression, and anemia. However, interstitial pneumonia, previously considered a risk factor, was not identified. When evaluating risks influenced by racial and treatment-related factors, caution must be exercised regarding potential discrepancies between reported rates and true incidence.

13 October 2025 in Oncology
Verified
Journal Article
Closed access
HAHiroki Asano
Hiroki Asano
Yoshihiro noguchiYoshihiro noguchi
Yoshihiro noguchi
RMRikuto Masuda
Rikuto Masuda
MGMakiko Go
Makiko Go
MKMichio Kimura
Michio Kimura
TYTomoaki Yoshimura
Tomoaki Yoshimura
Introduction: Anaplastic lymphoma kinase tyrosine kinase inhibitors (ALK-TKIs) have transformed the management of ALK-rearranged non-small-cell lung cancer (NSCLC), yet their cardiotoxicity profile remains incompletely characterized, particularly with respect to sex differences. Given the high prevalence of cardiovascular disease in patients with NSCLC, understanding potential sex-specific risks is critical. Methods: We conducted a pharmacovigilance analysis using the US FDA Adverse Event Reporting System (FAERS) database (Q1 2004–Q3 2021) to examine cardiotoxicity signals associated with five ALK-TKIs (alectinib, brigatinib, ceritinib, crizotinib, and lorlatinib). Adverse events were classified using the MedDRA hierarchy, focusing on cardiac disorders. Disproportionality analysis was performed via the Bayesian Confidence Propagation Neural Network (BCPNN) method, calculating Information Component (IC) scores. Sex differences were assessed by computing the IC delta and its 95% confidence interval. Results: Cardiotoxicity signals, particularly heart failure and pericardial disorders, were detected for alectinib, ceritinib, crizotinib, and lorlatinib but not brigatinib. Notably, significant female-specific signals emerged for left ventricular failure with alectinib; pericardial disorders with ceritinib and crizotinib; and heart failure not elsewhere classified (the MedDRA category used for heart failure cases that do not fall into specific classifications) with crizotinib. Conclusion: This is the first study to identify sex differences in ALK-TKI-associated cardiotoxicity, highlighting a consistent female predominance in reported adverse events. In particular, considering its widespread use and the clinical importance of left ventricular failure, the pronounced disproportionality signal of cardiotoxicity in females associated with alectinib is thought to have substantial clinical impact. These results underscore the need for heightened clinical vigilance and further research into sex-specific risk stratification and preventive strategies for cardiotoxicity in patients receiving ALK-TKIs.

14 September 2025 in Journal of Pineal Research
Verified
Journal Article
Closed access
Yoshihiro noguchiYoshihiro noguchi
Yoshihiro noguchi
RMRikuto Masuda
Rikuto Masuda
TYTomoaki Yoshimura
Tomoaki Yoshimura


29 September 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
TSTomoya Sugimoto
Tomoya Sugimoto
Yoshihiro noguchiYoshihiro noguchi
Yoshihiro noguchi
RMRikuto Masuda
Rikuto Masuda
STSorami Tani
Sorami Tani
THTomohiko Harada
Tomohiko Harada
TYTomoaki Yoshimura
Tomoaki Yoshimura
Background: Osimertinib is the standard of care for epidermal growth factor receptor mutation-positive non-small cell lung cancer, but heart failure hospitalization (HFH) remains a concern, and no practical tool exists to stratify HFH risk during therapy. Methods: In this retrospective cohort study using a Japanese claims database, 5802 patients newly initiating osimertinib were followed for HFH during treatment. Baseline predictors assessed before the index date were selected by 10-fold cross-validated least absolute shrinkage and selection operator (LASSO) logistic regression and internally validated by bootstrapping (B = 500), repeating predictor selection in each resample. Cumulative incidence functions and Fine–Gray models treated death as a competing event; cause-specific Cox models served as sensitivity analyses. Results: HFH occurred in 169 patients (2.9%) during a median on-treatment follow-up of 9.3 months, with 268 competing deaths. LASSO retained seven predictors. The apparent concordance index (C-index) was 0.731 (95% confidence interval, 0.691–0.771) and the optimism-corrected C-index 0.718. Observed incidence increased 10.2-fold across predicted-risk deciles (1.03–10.50%). Fine–Gray and Cox estimates closely matched the logistic model. Conclusions: Baseline cardiovascular vulnerability stratifies HFH risk during osimertinib therapy. The nomogram, not externally validated, is best used as a screening aid to identify patients who may benefit from intensified cardiovascular monitoring.